|By PR Newswire||
|February 18, 2014 04:15 AM EST||
- Third Phase of Collaboration Aims to Unravel Mysteries of Disease by Identifying Disease Markers and Potential New Drug Targets
FRAMINGHAM, Massachusetts and SUNNYVALE, California, Feb. 18, 2014 /PRNewswire/ -- Berg and the Parkinson's Institute and Clinical Center today announced the next phase in their ongoing partnership, focused on identifying potential biomarkers that may lead to breakthroughs in the research, diagnosis, and treatment of Parkinson's disease. Using Berg's Interrogative Biology™ platform to analyze multi-omic tissue samples (skin fibroblasts, blood, urine) supplied by the Parkinson's Institute, this collaboration will identify the differences between healthy and diseased tissues in an effort to unravel the mysteries of Parkinson's disease. Berg and the Parkinson's Institute together are the first teams to approach biomarker discovery by looking at proteomics, metabolomics, and lipidomics, in addition to clinical data, simultaneously in human patients and controls from the same cohort.
The new clinical study launched at the Parkinson's Institute and Clinical Center will collect urine, blood, and other relevant tissue samples from people living with Parkinson's disease. These materials will be used to validate biomarker candidates identified previously from the collaboration. Most importantly, this will represent a first in merging patients' molecular and clinical information to develop profiles that will drive the development of biomarkers.
Berg is a biopharmaceutical company committed to uncovering health solutions through a data-driven, biological research approach. The Parkinson's Institute is America's only independent, non-profit organization that brings together world-class care, laboratory research, clinical research, and clinical trials for Parkinson's disease under one roof.
"This partnership harnesses the exceptional clinical expertise and superior research resources of the Parkinson's Institute, along with Berg's unique ability to integrate patient-specific molecular data with clinical and demographic information," said Niven R. Narain, Co-Founder, President and Chief Technology Officer of Berg. "This new and exciting phase of our collaboration has the potential to create a number of game-changing innovations to better diagnose and manage Parkinson's disease."
Parkinson's disease is a progressive movement-related disorder of the central nervous system. It is estimated that there are approximately one million Americans living with Parkinson's. Each year, 50,000 new cases are diagnosed, and this rate is expected to rise with the aging baby boomer population. A clear understanding of Parkinson's and its underlying pathophysiology continues to be elusive as a result of the disease's complexity and a lack of predictive capability among existing models.
The expectation for this partnership is that it will help lead to a greater understanding of Parkinson's disease and the development of new tools that can change its course.
"Through our collaboration with Berg, we hope to identify predictors for the disease and potential new drug targets. Armed with this information, we will be able to better diagnose and develop therapies that can treat and perhaps even halt the neurological damage caused by Parkinson's, " said Birgitt Schuele, M.D., Director of Gene Discovery and Stem Cell Modeling at the Parkinson's Institute. "This collaboration is very exciting. Our discoveries have the potential to change the way we think about and approach Parkinson's disease."
One fundamental and defining contribution of the Berg-Parkinson's Institute collaboration will be to provide hallmark insights into disease pathophysiology.
"With diseases like cancer and diabetes, we at least have a foundational map and understanding of their pathways. Our challenge with most central nervous system (CNS) diseases is that there is a gross lack of understanding of the molecular pathways and drivers of disease pathophysiology. The anchor points are just not as clear as they are with other disease states," said Paula P. Narain, CNS Disease Program Lead at Berg. "This collaboration will lead to insights into disease mechanisms that will provide a solid foundation for biomarker and therapeutic candidate discovery. Berg is confident that the combination of tissue samples and expertise from the Parkinson's Institute, together with their award-winning Interrogative Biology™ platform, will usher in a paradigm shift in Parkinson's disease."
About the Berg Interrogative Biology™ Platform
Berg's application of machine-learning (Artificial Intelligence) in biology and medicine allows for a combination of systems biology and systems engineering leading to well defined answers on human health. The Berg Interrogative Biology™ platform integrates molecular data directly from a patient with clinical and demographic information to learn predictive patterns. The platform has the potential to provide the physician with actionable information to recommend efficient and safe treatment pathways, insurance companies with health economics analyses to develop more relevant formulary and governments with a data ecosystem for financial modeling of healthcare needs of the population.
Berg, the namesake of Carl Berg, is a biopharmaceutical company and parent company to Berg Pharma, Berg Biosystems and Berg Diagnostics. Our research focus seeks to understand how alterations in metabolism relate to disease onset. We have uncovered key insight into metabolic control factors and namely into underlying elements in the Warburg Hypothesis. The company has a deep pipeline of early-stage technologies in CNS diseases and metabolic diseases that complement its late-stage clinical trial activity in cancer and prevention of chemotoxicity. Armed with use of the discovery platform that translates biological output into viable therapeutics and a robust biomarker library, Berg is poised to realize its pursuit of a healthier tomorrow. For additional information, visit http://www.bergpharma.com/.
About the Parkinson's Institute and Clinical Center
Two and a half decades ago, a dedicated group of Parkinson's disease experts set out to create a better way to research and provide care for Parkinson's disease. We would go beyond your standard doctor-patient relationship. Patients would become partners in developing their care plans, improving their quality of life, and discovering new strategies to confront and manage their disease. Compassionate care would work hand in hand with cutting-edge research to seek answers, develop new therapies and treatments, and ultimately work toward a cure. Our result was the Parkinson's Institute and Clinical Center. Along the way, we have built something that's thoroughly unique. Our Institute is a place where people living with Parkinson's can both pursue their care and play an important role in research that will undoubtedly continue to change the landscape of Parkinson's science and medicine. We are America's only independent nonprofit organization combining world-class care, clinical research, and laboratory research for Parkinson's disease under one roof. By virtue of our design, we are uniquely equipped to provide the best care, accelerate promising science, and perhaps most important—integrate the two and everything in between. It's what we now call Our Virtuous Circle and people living with Parkinson's and their loved ones are at the center of all that we do.
Contact: Chris Wahlers, +1-212-880-5293, [email protected]
Apr. 24, 2017 07:15 AM EDT Reads: 1,923
SYS-CON Events announced today that T-Mobile will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. As America's Un-carrier, T-Mobile US, Inc., is redefining the way consumers and businesses buy wireless services through leading product and service innovation. The Company's advanced nationwide 4G LTE network delivers outstanding wireless experiences to 67.4 million customers who are unwilling to compromise on ...
Apr. 24, 2017 07:15 AM EDT
SYS-CON Events announced today that Juniper Networks (NYSE: JNPR), an industry leader in automated, scalable and secure networks, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Juniper Networks challenges the status quo with products, solutions and services that transform the economics of networking. The company co-innovates with customers and partners to deliver automated, scalable and secure network...
Apr. 24, 2017 07:00 AM EDT
“DevOps is really about the business. The business is under pressure today, competitively in the marketplace to respond to the expectations of the customer. The business is driving IT and the problem is that IT isn't responding fast enough," explained Mark Levy, Senior Product Marketing Manager at Serena Software, in this SYS-CON.tv interview at DevOps Summit, held Nov 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.
Apr. 24, 2017 06:45 AM EDT Reads: 16,058
20th Cloud Expo, taking place June 6-8, 2017, at the Javits Center in New York City, NY, will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud strategy.
Apr. 24, 2017 06:15 AM EDT Reads: 2,834
Apr. 24, 2017 06:00 AM EDT Reads: 142
@GonzalezCarmen has been ranked the Number One Influencer and @ThingsExpo has been named the Number One Brand in the “M2M 2016: Top 100 Influencers and Brands” by Analytic. Onalytica analyzed tweets over the last 6 months mentioning the keywords M2M OR “Machine to Machine.” They then identified the top 100 most influential brands and individuals leading the discussion on Twitter.
Apr. 24, 2017 05:15 AM EDT Reads: 188
SYS-CON Events announced today that Grape Up will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct. 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Grape Up is a software company specializing in cloud native application development and professional services related to Cloud Foundry PaaS. With five expert teams that operate in various sectors of the market across the U.S. and Europe, Grape Up works with a variety of customers from emergi...
Apr. 24, 2017 05:00 AM EDT Reads: 1,706
The 20th International Cloud Expo has announced that its Call for Papers is open. Cloud Expo, to be held June 6-8, 2017, at the Javits Center in New York City, brings together Cloud Computing, Big Data, Internet of Things, DevOps, Containers, Microservices and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding business opportunity. Submit your speaking proposal ...
Apr. 24, 2017 04:45 AM EDT Reads: 220
With major technology companies and startups seriously embracing IoT strategies, now is the perfect time to attend @ThingsExpo 2016 in New York. Learn what is going on, contribute to the discussions, and ensure that your enterprise is as "IoT-Ready" as it can be! Internet of @ThingsExpo, taking place June 6-8, 2017, at the Javits Center in New York City, New York, is co-located with 20th Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry p...
Apr. 24, 2017 04:15 AM EDT Reads: 218
SYS-CON Events announced today that Super Micro Computer, Inc., a global leader in compute, storage and networking technologies, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Supermicro (NASDAQ: SMCI), the leading innovator in high-performance, high-efficiency server technology, is a premier provider of advanced server Building Block Solutions® for Data Center, Cloud Computing, Enterprise IT, Hadoop/...
Apr. 24, 2017 04:15 AM EDT Reads: 1,828
Amazon has gradually rolled out parts of its IoT offerings in the last year, but these are just the tip of the iceberg. In addition to optimizing their back-end AWS offerings, Amazon is laying the ground work to be a major force in IoT – especially in the connected home and office. Amazon is extending its reach by building on its dominant Cloud IoT platform, its Dash Button strategy, recently announced Replenishment Services, the Echo/Alexa voice recognition control platform, the 6-7 strategic...
Apr. 24, 2017 04:00 AM EDT Reads: 4,833
Bert Loomis was a visionary. This general session will highlight how Bert Loomis and people like him inspire us to build great things with small inventions. In their general session at 19th Cloud Expo, Harold Hannon, Architect at IBM Bluemix, and Michael O'Neill, Strategic Business Development at Nvidia, discussed the accelerating pace of AI development and how IBM Cloud and NVIDIA are partnering to bring AI capabilities to "every day," on-demand. They also reviewed two "free infrastructure" pr...
Apr. 24, 2017 02:45 AM EDT Reads: 883
In his keynote at @ThingsExpo, Chris Matthieu, Director of IoT Engineering at Citrix and co-founder and CTO of Octoblu, focused on building an IoT platform and company. He provided a behind-the-scenes look at Octoblu’s platform, business, and pivots along the way (including the Citrix acquisition of Octoblu).
Apr. 24, 2017 02:45 AM EDT Reads: 839
Everyone wants to use containers, but monitoring containers is hard. New ephemeral architecture introduces new challenges in how monitoring tools need to monitor and visualize containers, so your team can make sense of everything. In his session at @DevOpsSummit, David Gildeh, co-founder and CEO of Outlyer, will go through the challenges and show there is light at the end of the tunnel if you use the right tools and understand what you need to be monitoring to successfully use containers in your...
Apr. 24, 2017 01:15 AM EDT Reads: 1,712